» Articles » PMID: 36514068

Outcomes and Risk Factors with COVID-19 or Influenza in Hospitalized Asthma Patients

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2022 Dec 13
PMID 36514068
Authors
Affiliations
Soon will be listed here.
Abstract

Background: At the time of the SARS-CoV-2 emergence, asthma patients were initially considered vulnerable because respiratory viruses, especially influenza, are associated with asthma exacerbations, increased risk of hospitalization and more severe disease course. We aimed to compare the asthma prevalence in patients hospitalized for COVID-19 or influenza and risk factors associated with poor prognosis with the diseases.

Methods: This retrospective cohort study used the Paris university hospitals clinical data warehouse to identify adults hospitalized for COVID-19 (January to June 2020) or influenza (November 2017 to March 2018 for the 2017-2018 influenza period and November 2018 to March 2019 for the 2018-2019 period). Asthma patients were identified with J45 and J46 ICD-10 codes. Poor outcomes were defined as admission in intensive care or death.

Results: Asthma prevalence was significantly higher among influenza than COVID-19 patients (n = 283/3 119, 9.1%, 95% CI [8.1-10.1] in 2017-2018 and n = 309/3 266, 9.5%, 95% CI [8.5-10.5] in 2018-2019 versus n = 402/9 009, 4.5%, 95% CI [4.0-4.9]). For asthma patients, 31% with COVID-19 were admitted to an intensive care unit versus 23% and 21% with influenza. Obesity was a risk factor for the 2017-2018 influenza period, smoking and heart failure for the 2018-2019 period. Among COVID-19 patients with asthma, smoking and obesity were risk factors for the severe form.

Conclusions: In this study, patients with an asthma ICD-10 code were less represented among COVID-19 patients than among influenza-infected ones. However, outcomes were poorer for COVID-19 than influenza patients, both with asthma. These data highlight the importance of protective shields and vaccination against influenza and COVID-19 in this population.

Citing Articles

Differences in clinical characteristics between coronavirus disease 2019 (COVID-19) and influenza: a systematic review and meta-analysis.

Han Y, Guo J, Li X, Zhong Z NPJ Prim Care Respir Med. 2025; 35(1):8.

PMID: 39875405 PMC: 11775258. DOI: 10.1038/s41533-025-00414-0.


2024 Public Health Actions to Reduce the Burden of Asthma: Influenza and COVID-19 Vaccination Uptake Among People with Asthma.

Jaffee H, Eftekhari S, Carver M Prev Chronic Dis. 2024; 21:E59.

PMID: 39117351 PMC: 11318950. DOI: 10.5888/pcd21.240058.


Asthma and Susceptibility to COVID-19 in Australian Children During Alpha, Delta and Omicron Waves of the COVID-19 Pandemic.

Chan M, Owens L, Gray M, Selvadurai H, Jaffe A, Homaira N J Asthma Allergy. 2023; 16:1139-1155.

PMID: 37854297 PMC: 10581009. DOI: 10.2147/JAA.S421158.

References
1.
McPherson K, Carlos 3rd W, Emmett T, Slaven J, Torke A . Limitation of Life-Sustaining Care in the Critically Ill: A Systematic Review of the Literature. J Hosp Med. 2019; 14(5):303-310. PMC: 6625435. DOI: 10.12788/jhm.3137. View

2.
Jhung M, Swerdlow D, Olsen S, Jernigan D, Biggerstaff M, Kamimoto L . Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011; 52 Suppl 1:S13-26. DOI: 10.1093/cid/ciq008. View

3.
Banerjee D, Chung S, Wong E, Wang E, Stafford R, Palaniappan L . Underdiagnosis of hypertension using electronic health records. Am J Hypertens. 2011; 25(1):97-102. PMC: 3600431. DOI: 10.1038/ajh.2011.179. View

4.
Edwards M, Strong K, Cameron A, Walton R, Jackson D, Johnston S . Viral infections in allergy and immunology: How allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017; 140(4):909-920. PMC: 7173222. DOI: 10.1016/j.jaci.2017.07.025. View

5.
Kimura H, Francisco D, Conway M, Martinez F, Vercelli D, Polverino F . Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol. 2020; 146(1):80-88.e8. PMC: 7227558. DOI: 10.1016/j.jaci.2020.05.004. View